Medicus Pharma closes $4.2M Reg A offering of 1.49M units at $2.80/unit

Medicus Pharma Ltd.

Gross proceeds $4,172,000 from 1,490,000 units (one share + one warrant) priced at $2.80/unit; closed March 10, 2025.
Warrants exercisable at $2.80/share for 5 years from issuance; not listed on any exchange.
Net proceeds to fund Phase 2 proof-of-concept trial for basal cell carcinoma using doxorubicin microarray needle patch.
Maxim Group LLC lead placement agent; customary 7.5% cash fee plus expense reimbursement.
Offering qualified under Tier II Regulation A on March 6, 2025; subscription agreement with a single investor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.